Tencent Music Entertainment Group to Hold Annual General Meeting on June 27, 2025
SHENZHEN, China, May 20, 2025 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that it will hold its annual general meeting of shareholders (the "AGM") at 10/F, The Hong Kong Club Building, 3A Chater Road, Central, Hong Kong on Friday, June 27, 2025 at 10 a.m. (Beijing/Hong Kong time) for the purposes of considering and, if thought fit, passing the resolutions as set forth in the notice of the AGM (the "AGM Notice"). The AGM Notice and the form of proxy for the AGM are available on the Company's website at https://ir.tencentmusic.com on May 20, 2025. The Board of Directors of the Company fully supports the proposed resolutions and recommends that shareholders and holders of American depositary shares ("ADSs") vote in favor of the resolutions.
Holders of record of the Company's ordinary shares as of the close of business on Tuesday, May 20, 2025 (Beijing/Hong Kong time), are entitled to receive notice of, and to attend and vote at, the AGM or any adjournment or postponement thereof. Holders of record of ADSs as of the close of business on Tuesday, May 20, 2025 (U.S. Eastern Time) who wish to exercise their voting rights for the underlying Class A ordinary shares must give voting instructions directly to The Bank of New York Mellon, the depositary of the ADSs, or indirectly through a bank, brokerage or other securities intermediary, as the case may be.
The Company has filed its annual report on Form 20-F, including its audited financial statements, for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the "SEC"). The Company's annual report on Form 20-F can be accessed on the Company's website at https://ir.tencentmusic.com and on the SEC's website at https://www.sec.gov.
About Tencent Music Entertainment
Tencent Music Entertainment Group (NYSE: TME and HKEX: 1698) is the leading online music and audio entertainment platform in China, operating the country's highly popular and innovative music apps: QQ Music, Kugou Music, Kuwo Music and WeSing. TME's mission is to create endless possibilities with music and technology. TME's platform comprises online music, online audio, online karaoke, music-centric live streaming and online concert services, enabling music fans to discover, listen, sing, watch, perform and socialize around music. For more information, please visit ir.tencentmusic.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC and the HKEX. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
Investor Relations Contact
Tencent Music Entertainment Groupir@tencentmusic.com +86 (755) 8601-3388 ext. 818415
View original content:https://www.prnewswire.com/news-releases/tencent-music-entertainment-group-to-hold-annual-general-meeting-on-june-27-2025-302460015.html
SOURCE Tencent Music Entertainment Group
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Valerie Mahaffey has died at the age of 71
Valerie Mahaffey - best known for her roles in 'Northern Exposure' and 'Big Sky - has died at the age of 71.
Yahoo
an hour ago
- Yahoo
Boston Rob Turned Down ‘Survivor 50' Offer Because ‘I Wanted My Spot to Go to Someone Who Deserved Another Chance,' Tells Fans: ‘Don't Be Mad'
'Survivor' announced its cast this week for the show's 50th season, but not every fan was too pleased with who got invited to come back. While the return of 'The White Lotus' creator Mike White and fan favorites like Cirie Fields and Ozzy Lusth generated excitement, the omission of iconic players like Rob Mariano (aka Boston Rob), Parvati Shallow and more left many fans scratching their heads as they wondered why so many players from older seasons of 'Survivor' were not included. Boston Rob, whose reality show career has flourished in recent years with appearances on 'The Traitors' and more, has now taken to Instagram to explain his absence from 'Survivor 50.' It turns out the show did ask him to return, but he made the decision to opt out in order to give other players their chance to return to the 'Survivor' spotlight. More from Variety 'Survivor 49' Cast Includes 'Black Panther' Producer and Former Marvel Exec Nate Moore Jeff Probst on Why He Worried 'Survivor' Was 'Doomed' After Season 1, What Season 50 Gameplay He Hopes Fans Vote For and Whether a Live Finale Could Return Jeff Probst's First-Ever Tears on Air Bring 'Survivor' to a Season High of 4.5 Million Viewers 'Wow!!! I got all of your DM's and messages so so many thank you all!! But literally don't be mad,' Boston Rob wrote in a message to fans. ''Survivor' and Jeff Probst early on they called and asked… I just felt like I have played so many times and I am truly fulfilled with my 'Survivor' journey. I wanted my spot to go to someone else that deserved another chance!' 'I've gotten so much out of 'Survivor,'' he added. 'It will always be a part of who I am! I'm eternally grateful. Like I said ..It's gonna be OK. I feel like something good is coming!!!' Boston Rob is one of 'Survivor's' most prolific contestants and the only one to compete on five seasons of the show. He debuted in Season 4, 'Survivor: Marquesas,' and placed 10th, before returning for the first time in Season 8's 'Survivor: All-Stars' and being the runner-up. He appeared on 'Survivors: Heroes vs. Villains' (13th place) and won 'Survivor: Redemption' before serving as a mentor on 'Survivor: Island.' His last appearance on the show was Season 40, 'Survivor: Winners at War.' 'Survivor 50' will feature 24 returning players and will premiere on CBS in Spring 2026. The milestone anniversary season promises to 'push the series into uncharted territory and impact the players like never before.' For the first time, the game is also being planned by the fans. Earlier this year, fans were able to vote on key elements of the game, including on whether there will be idols, whether fire making will remain and whether the live finale and reunion show will return in Los Angeles. The 'Survivor 50' contestants will compete for a $1 million cash prize. See the full 'Survivor 50' cast here. View this post on Instagram A post shared by Boston Rob Mariano (@bostonrobmariano) Best of Variety What's Coming to Netflix in June 2025 New Movies Out Now in Theaters: What to See This Week 'Harry Potter' TV Show Cast Guide: Who's Who in Hogwarts?
Medscape
2 hours ago
- Medscape
CAR T-Cell Therapy Boosts PFS in Advanced Gastric Cancer
In patients with advanced Claudin-18 isoform 2 (CLDN18.2) -positive gastric or gastroesophageal junction cancers, satricabtagene autoleucel (satri-cel) chimeric antigen receptor (CAR) T-cell therapy significantly extended progression-free survival (PFS) compared with treatment of physician's choice (TPC). METHODOLOGY CLDN18.2, a tight-junction protein, is overexpressed in patients with gastric and gastroesophageal junction (GEJ) cancers. Satri-cel, an autologous CLDN18.2-specific CAR T-cell therapy, showed promise in previously treated patients with advanced disease, but further validation is needed. The new phase 2 randomized controlled trial involved 156 patients with pathologically confirmed CLDN18.2-positive advanced gastric or GEJ cancer who were refractory to two or more previous lines of treatment. The study was conducted in multiple centers in China, and the median age of participants was 52 years. Participants were randomly assigned in a 2:1 ratio to receive either satri-cel (IV infusion, up to three times at 250 × 10 6 cells; n = 104) or TPC (n = 52) that included nivolumab, paclitaxel, docetaxel, irinotecan, or rivoceranib. cells; n = 104) or TPC (n = 52) that included nivolumab, paclitaxel, docetaxel, irinotecan, or rivoceranib. In the satri-cel group, 85% of patients received at least one infusion of satri-cel, 31% received a second infusion, and 6% received a third infusion. In the TPC group, 92% of patients received at least one dose of their treatment. The primary endpoint was PFS assessed by a blinded independent review committee. The key secondary endpoint was overall survival (OS). The median follow-up time for PFS was 9.07 months in the satri-cel group and 3.45 months in the TPC group. The median follow-up time for OS was 14.42 months and 11.33 months in the satri-cel and TPC groups, respectively. TAKEAWAY In the intention-to-treat population, the median PFS was 3.25 months in the satri-cel group and 1.77 months in the TPC group. Satri-cel reduced the risk for progression or death by 63% (hazard ratio [HR], 0.37; P < .0001). Median OS showed improvement with satri-cel vs TPC (7.92 vs 5.49 months), although it did not reach statistical significance (HR, 0.69; P = .0416). < .0001). Median OS showed improvement with satri-cel vs TPC (7.92 vs 5.49 months), although it did not reach statistical significance (HR, 0.69; = .0416). The objective response rate was notably higher in the satri-cel group than in the TPC group (22% vs 4%), with disease control rates of 63% and 25%, respectively. The median duration of response was 5.52 months in the satri-cel group. Only two patients in the TPC group showed a partial response, with durations of 4.47 months and 5.42 months, respectively. The median duration of disease control was 3.61 months and 4.27 months in the satri-cel and TPC groups, respectively. All patients in the satri-cel group experienced treatment-emergent adverse events compared with 92% in the TPC group. Grade 3 or higher adverse events occurred in 99% of patients in the satri-cel group and 63% of those in the TPC group; the most common ones were decreased lymphocyte count (99%), decreased white blood cell count (98%), and cytokine release syndrome (95%). IN PRACTICE In this randomized, phase 2 study, "satri-cel was associated with a statistically significant increase in progression-free survival and clinically meaningful increase in overall survival compared with TPC, along with a manageable safety profile in patients with previously treated, advanced, CLDN18.2-positive gastric or gastroesophageal junction cancer," the authors write. SOURCE The study, led by Changsong Qi, MD, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumour, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute in Beijing, China, was published online May 31 in The Lancet . LIMITATIONS The sample size — powered for PFS — might be insufficient to yield definitive conclusions from the subgroup analyses. Some patients in the satri-cel group could not receive CAR T-cell infusion after apheresis, making them ineligible for treatment. The time between apheresis and CAR T-cell infusion remains a significant limiting factor, particularly in the case of those experiencing rapid disease progression. DISCLOSURES The study was funded by CARsgen Therapeutics, the National Key Research and Development Program of China, the National Natural Science Foundation of China, Beijing Hospitals Authority Youth Programme, Science Foundation of Peking University Cancer Hospital, Clinical Medicine Plus X—Young Scholars Project of Peking University, and the Peking University Clinical Scientist Training Program. Five authors declared being employees of CARsgen Therapeutics. The other authors declared no competing interests.
